Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360 Psychedelics Investing
Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition Psychedelics Investing
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression and Clinical Trial Plans for Post-Traumatic Stress Disorder on January 7, 2026, 10:00am ET Psychedelics Investing
Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD Psychedelics Investing
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months Psychedelics Investing
NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression Psychedelics Investing
Right Season Investments Engages MCS Market Communication Service to Provide Market Support Psychedelics Investing
